Glioma
📧 Sign up to get email alerts when something new happens for Glioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma [NA]
A clinical trial evaluating blood-brain barrier disruption for suspected infiltrating glioma sponsored by InSightec has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-17Clinical Trial Update: Spectroscopic Magnetic Resonance Imaging of Glioma
The clinical trial investigating spectroscopic MRI for glioma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-01-15Clinical Trial Update: Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G) [EARLY_Phase 1]
The APATIT-G early phase 1 trial evaluating avatrombopag for temozolomide-induced thrombocytopenia in glioma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-09Clinical Trial Update: StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord [Phase 1]
Phase 1 trial evaluating StrataXRT to prevent radiation dermatitis in pediatric patients undergoing brain or spinal irradiation has been wit…
-
EMA withdrawal · 2023-03-06EMA Withdrawn: Temozolomide Sandoz (temozolomide) — Sandoz GmbH
EMA withdrew Temozolomide Sandoz (temozolomide) from the market; therapeutic area Glioma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2023-02-27EMA Withdrawn: Temozolomide Hexal (temozolomide) — Hexal AG
Temozolomide Hexal has been withdrawn from the market by Hexal AG in Europe for glioma.
-
EMA withdrawal · 2022-06-17EMA Application withdrawn: Sitoiganap (allogeneic glioma tumor cell lysates (inactivated);allogeneic glioma tumor cells (inactivated);autologous glioma tumor cell lysates (inactivated);autologous glioma tumor cells (inactivated)) — Epitopoietic Research Corporation-Belgium (E.R.C.)
The EMA has withdrawn the application for Sitoiganap, an immunotherapy consisting of inactivated allogeneic/autologous glioma tumor cell lys…
-
CLINICAL_TRIALS withdrawal · 2019-02-06Clinical Trial Update: Confocal Laser Endomicroscopy (CLE) During Medically Induced Neurosurgery in Craniobasal and Glioma Tumours
The clinical trial evaluating Confocal Laser Endomicroscopy during medically induced neurosurgery for glioma and related brain tumors has be…
-
CLINICAL_TRIALS withdrawal · 2017-10-11Clinical Trial Update: Phase 2 Study of IDH305 in Low Grade Gliomas [Phase 2]
Phase 2 study of IDH305 for low-grade gliomas has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-02Clinical Trial Update: A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors [Phase 1]
A Phase I pediatric trial of IMC-A12 (cixutumumab) in combination with temsirolimus for recurrent or refractory solid tumors has been withdr…
-
CLINICAL_TRIALS withdrawal · 2016-09-28Clinical Trial Update: C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating C11-sodium acetate PET/CT imaging for brain glioma, post-therapy necrosis, and pseudo-progressio…
-
CLINICAL_TRIALS withdrawal · 2016-05-17Clinical Trial Update: More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery [Phase 2]
A Phase 2 trial investigating fluorescence-guided surgery for removing malignant brain tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-26Clinical Trial Update: Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma [NA]
The clinical trial comparing Fluoro-L-thymidine PET imaging with advanced magnetic resonance techniques for recurrent glioma has been withdr…
-
CLINICAL_TRIALS withdrawal · 2015-07-29Clinical Trial Update: MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806 [NA]
A clinical trial evaluating the brain effects of efaproxiral in patients with recurrent or progressive glioma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-05-22Clinical Trial Update: Valproic Acid in Childhood Progressive Brain Tumors [Phase 1]
The trial withdrawal notice states that the Phase 1 study of valproic acid for childhood progressive brain tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-02-25Clinical Trial Update: Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma [Phase 2]
The Phase 2 open-label study of the radiopharmaceutical I-131-CLR1404 in recurrent glioma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-05-06Clinical Trial Update: Coping With High Grade Glioma [NA]
This is a clinical trial update indicating the study on coping with high-grade glioma has been terminated. The sponsor is Duke University.
-
CLINICAL_TRIALS withdrawal · 2012-11-21Clinical Trial Update: Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma [Phase 1]
A Phase I trial of dasatinib in combination with protracted temozolomide for recurrent malignant glioma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-04-24Clinical Trial Update: Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
A clinical trial investigating Vascular Endothelial Growth Factor (VEGF) levels in brain tumor patients has been withdrawn.
-
EMA withdrawal · 2008-12-04EMA Application withdrawn: Theraloc (nimotuzumab) — Oncoscience AG
An EMA application for Theraloc (nimotuzumab) by Oncoscience AG has been withdrawn for the glioma indication.
-
CLINICAL_TRIALS withdrawal · 2008-01-03Clinical Trial Update: XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema [Phase 3]
Phase 3 trial of XERECEPT (human corticotropin-releasing factor) in primary glioma patients requiring dexamethasone to treat peritumoral bra…
-
EMA withdrawal · 2007-07-20EMA Application withdrawn: Cerepro (adenovirus-mediated Herpes simplex virus-thymidine kinase gene) — Ark Therapeutics
EMA withdrew the Cerepro gene therapy application for glioma from Ark Therapeutics.